Tag: Gain-of-Function

Health Friday 4.17.2026 Open Thread: The Sleight-of-Hand at HHS Must Stop. Now.

The vintage image of mass vaccination for today’s offering is courtesy of Google Images.

Health Friday is a series on information regarding Big Pharma, vaccines, general health, and associated topics. There are Important Notifications from our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering, if any, will be cited as such. If readers wish to post AI-generated items in today’s discussion thread, they must cite their source. Thank you.

The United States Department of Health and Human Services (HHS) is still funding Gain-of-Function research. This is despite the 5 May 2025 directive from the White House regarding pausing all Gain-of-Function research by HHS (https://www.whitehouse.gov/presidential-actions/2025/05/improving-the-safety-and-security-of-biological-research/.) Examples: Arcturus Therapeutics is still under a “Fast Track” status granted to the company in April 2025 by the FDA — a Fast Track status granted for the development and testing of the company’s self-amplifying RNA (saRNA) “influenza vaccine”, ARCT-2304 (also known as, LUNAR-FLU or as LUNAR-H5N1 (https://ir.acrturus.com/news-releases/news-release-details/acturus-therapeutics-receives-us-fda-fast-track-designation-0, 10 April 2025.)

Yours Truly begins here: https://jonfleetwood.substack.com/p/hhs-funds-gain-of-function-influenzacovid, “HHS Funds Gain-of-Function Influenza — COVID ‘Frankenvirus’ Combining Influenza Entry With SARS-CoV-2 Human Cell – Binding Domain”, 10 April 2026. Two screenshots regarding this are below: the first, from the Fleetwood article; the second, from the paper itself (published December 2025). Thanks to Mr. Fleetwood for this information:

By the way, NIH grant P01-AI165075 (going to Rockefeller University, New York) has multiple “permutations” in the https://reporter.nih.gov/ listing. **** The “permutation” that helped to fund the paper below (cited in the Fleetwood article) is 3P01AI165075 – 01S1, Sub-Project ID: 6568, awarding entity NIAID, total funding: $983,100. (And this is only ONE “permutation” of P01-AI165075.)

**** What this lab-created “combo virus”, called X31 H3 S-RBD in the paper, contains:

The RBD (Receptor Binding Domain) from the Wuhan Hu1 SARS-CoV-2 virus (the original COVID-19 virus); plus

Seven other viral RNAs (vRNAs) from the H1N1 (Influenza A) Puerto Rico/1/1934 strain (PR8)

The Abstract of this paper is below. It is a clear statement that Gain-of-Function was used to lab-create this “combo virus” (lines 28 – 35):

Let’s take a look at the involvement with the Chinese Academy of Medical Sciences (CAMS) in the study that produced this paper. The paper states that Tiong Kit Tan, of the Chinese Academy of Sciences – Oxford Institute, Nuffield Department of Medicine, University of Oxford, is one of the researchers/co-authors. CAMS is a collaborator with the Chinese Communist People’s Liberation Army (PLA.) CAMS is one of the “Top 5” domestic (Chinese-based) collaborators with the PLA. Please see: https://www.nature.com/nature-index/institution-outputs/china/people-s-liberation-army-pla/555c2052140ba014648b456b; scroll down the page to the list of “Domestic Collaborators.”

Further down the page, there is the list of “International Collaborators” with the PLA. It is interesting to note that NUS (National University of Singapore) is ranked as Number One here. It is also interesting to note that NUS has a large medical school that is a “satellite” of Duke University (Chapel Hill, North Carolina; https://www.duke-nus.edu.sg.)

CAMS also has ties to Yale University via the CMB Foundation Global Health Research Fellowship in Communist China (https://medicine.yale.edu/education/othereducation/cmb/foundation-global-health-research-fellowship-in-china/cams-pumc/; PUMC is Peking Union Medical College); to Harvard Medical School; and, to the NIH (https://www.science.org/cms/asset/ecaa3321-8b14-45e9-b549-1631422a83ea/cams_booklet_2016_11_18.pdf, pages 44-45.)

The question arises: How much research data, analyses, lab samples, and more, from these “international collaborators” with the Chinese Academy of Medical Sciences, wind up in laboratories run by the People’s Liberation Army in hospitals and universities throughout Communist China?

>>>>>>>>>>>>>>>>>>>>

Let’s look at a recent example of “Gain-of-Function Experiments Gone Wrong”: https://childrenshealthdefense.org/defender/exclusive-bird-flu-outbreak-40-miles-wisconsin-lab-sparks-concern-gain-of-function-experiments/, “Exclusive: Bird Flu Outbreak 40 Miles From Wisconsin Lab Sparks Concern About Gain-of-Function Experiments”, Michael Devradakis, PhD, 15 January 2026. A screenshot from this article is below:

Yoshihiro Kawaoka, DVM, PhD, is also the scientist who is heavily involved with Gain-of-Function experiments at the University of Wisconsin-Madison. And, that there is a record of prior accidents and leaks from his lab there: https://www.cidrap.umn.edu/biosecurity-issues/wisconsin-lab-broke-ebola-rules-watchdog-group-says, 25 September 2007; and, https://www.wispolitics.com/2023/wisconsin-congressional-republicans-demand-answers-on-biosafety-incident-at-uw-madison/, 23 April 2023.

The NIH grant that helped to fund Dr. Kawaoka’s work for the above cited paper is 75N93021C00014. The grant contract information is found here: https://www.highergov.com/contract/759321C00014/. An image of the Government Description of this grant, from the website, is below:

Note that sentence about, “Includes international and domestic basic and clinical influenza research…” — in other words, covering “collaborators” like CAMS. Note that “studies of viral evolution, transmission, and immune responses in animal models and humans” covers Gain-of-Function work.

CEIRR stands for Centers of Excellence for Influenza Research and Response. The website description of this research division of NIAID is here: https://www.niaid.nih.gov/research/centers-excellence-influenza-research-response. Scroll down the page to “Main Areas of Focus” to this statement: “To support projects to determine how influenza viruses evolve, adapt and transmit between humans and at interspecies interfaces”. This is “code” for supporting Gain-of-Function research on influenza viruses. There are multiple “permutations” of NIH grant 75N93021C00014 listed at https://reporter.nih.gov/search/6vlkhZH5302zeKPiGnsO5g/projects, most of which were awarded to the Icahn School of Medicine at Mount Sinai, New York (one of the CEIRR main hubs of research.)

>>>>>>>>>>>>>>>>>>>>

Yours Truly turns to what might be, in her opinion, called a “permutation” of Gain-of-Function research: experiments on human beings to further a Patent invention.

The Patent in question is: US11369675B2, “Broadly protective inactivated influenza virus vaccine”, held by Dr. Jeffery Taubenberger, MD, Acting Director of NIAID. The Patent declaration is found here: https://patents.google.com/patent/US11369675B2/en. The application for the Patent was filed on 12 October 2020; the Patent was granted on 28 June 2022; the “Adjusted expiration” date of the Patent is 24 January 2039; and, the Patent was assigned to the Department of Health and Human Services (HHS.) Dr. Taubenberger, during this timeline, was an employee of HHS, before he became Acting Director of NIAID. He, in fact, is a career HHS (NIH) employee.

Dr. Taubenberger’s Patent describes a “universal influenza vaccine.” Yours Truly has written on this situation; for example: https://www.theqtree.com/2025/05/16/health-friday-open-thread-5-16-2025-about-that-universal-vaccine-theres-more-than-meets-the-eye-part-two/.

It appears that Dr. Taubenberger is working to further the Patent regarding the development of an intranasal “universal influenza vaccine.” His most recent published paper in this regard is here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12375958/S#23, “Nasal and systemic immune responses correlate with viral shedding after influenza challenge in people with complex preexisting immunity”, Jeffery Taubenberger, et al., 6 August 2025. This paper describes a very small study of 74 persons (originally 80 persons) that was conducted in 2019 per the cited paper above (NCT01971255.) However, the ACTUAL study dates of NCT01971255, per https://clinicaltrials.gov/study/NCT01971255, indicate a timeframe between September 2013 and September 2015. In addition, the referenced paper number 11 in the cited paper above describes the same experimental study, but via a paper published about it in 2024 (https://pmc.ncbi.nlm.nih.gov/article/PMC10865821/, “Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers”, Jeffery Taubenberger, et al., 9 January 2024.) This, to Yours Truly, raises questions regarding the timing of the publishing of these papers, since the actual study was conducted over 10 years ago. What goes on here?

The bottom lines of NCT10971255: there were 80 enrolled study subjects; half were vaccinated with a licensed influenza “vaccine”; half were unvaccinated; ALL subjects were then given an intranasal LIVE VIRUS H1N1 (swine flu), called Ca/04/2009/H1N1r Challenge Virus; ALL subjects were then tested numerous times via a middle turbinate nasal swab (this means that the swab samples were taken from well inside the upper nasal cavity each time); apparently, ALL subjects became ill with flu symptoms, some of which were severe; 6 study subjects withdrew for various reasons; all testing using the “intranasal challenge virus” was performed at the NIH Clinical Center in Bethesda, Maryland; the study subjects were brought there for the “challenge” (and likely had to stay there or in the immediate area, as they were assessed daily for a minimum of 9 days.)

Yours Truly will point out that Patent holders at HHS (NIH; NIAID) can earn significant royalty payments for the use of the their registered inventions. Please see: https://www.lankford.senate.gov/news/press-releases/lankford-hsgac/republicans-request-information-from-nih-on-the-disclosure-of-royalty-payments-to-nih-employees/, 1 June 2022.

Dr. Taubenberger is the recipient of NIAID research funding related to Avian Influenza viruses, his “universal influenza vaccine”, and to the SARS-CoV-2 virus — in the 2025 fiscal year, among other years. However, 2025 is the year in which Dr. Taubenberger became the Acting Director of NIAID. The “umbrella grant” prefix number is either 1ZIAAI00 or 1ZIAAI000, each followed with the suffix number: for example, 1ZIAAI001372-03, “Universal Influenza Vaccine Development”, for $2,153,677. This grant, as at least one other per https://reporter.nih.gov/ (search: Jeffery Taubenberger), lists NO contact data; NO Project Start Date; NO DUNS number; NO Budget End Date; among other lack of public information. What goes on here? Is Dr. Taubenberger perhaps granting NIAID research funds to himself?

>>>>>>>>>>>>>>>>>>>>

Finally, is appears that HHS Sec. Robert F. Kennedy, Jr., is going to start a podcast:

Sec. Kennedy, Jr., states that he will “…ask the questions and lift the taboos and expose the hypocrisy and the conflicts and the corruption…We’re going to follow the evidence wherever it leads, and we’re going to name the names of the forces that obstruct the paths to public health.”

All well and good. However — will Sec. Kennedy, Jr., “name the names”, such as: the person who invented the SARS-CoV-2 virus itself — Dr. Ralph Baric of the University of North Carolina, Chapel Hill? Such as, the person who could have stopped the entire COVID-19 “vaccine” disaster in the United States in December 2020, but who instead signed off on the CDC’s “recommendation” for the use of Pfizer-BioNTech’s modRNA COVID-19 bioweapon “vaccine”, BNT162b2, without any further investigation — Dr. Robert Redfield, then-Director of the CDC? Such as, the person who was responsible for the NIAID funding that produced the SARS-CoV-2 virus itself — Dr. Anthony Fauci, former NIAID Director? Such as, the USAMRIID personnel responsible for working with PfizerUSA (Pfizer-BioNTech) in the development of BNT162b2? Will Sec. Kennedy, Jr., “name the names” of the products that, by far, have obstructed, and continue to obstruct, “the paths to public health” — the COVID-19 bioweapon “vaccines”?

ALL GAIN-OF-FUNCTION WORK IN THE UNITED STATES, OF ANY TYPE, MUST BE STOPPED. NOW.

Peace, Good Energy, Respect: PAVACA

(Intellectual Property Disclosure and Notice: Except for the linked URLs and other items that can be found in the Internet, the ideas and/or opinions of today’s offering are by PAVACA. Credit must be given to PAVACA if the ideas and/or opinions of today’s offering are used by other blog writers, podcasters, or in social or print media.)

Health Friday 10.11.2024: About The Bird Flu Summit This Month in Virginia

The above blurred image of persons attending a conference is courtesy of Google Images and Vecteezy.

Today’s Health Friday offering is one a of a series devoted to Big Pharma, vaccines, general health, and associated topics. The discussion is not limited to what is presented in today’s post: it is an Open Thread.

There are Important Wolf Moon Notifications; the Rules of our late, good Wheatie; and other items that readers should be familiar with. They are all linked here.

This post will be diving into some “interesting” rabbit-holes. Stay with Yours Truly — I believe they are all interconnected. There is a General Summary at the end of the post.

The trail, for today’s purposes, begins with the following links: www.theburningplatform.com/2024/10/04/exclusive-new-york-city-health-officials-to-hold-bird-flu-tabletop-exercise/, 4 October 2024, by Michael Nevradakis, Ph.D.; https://childrenshealthdefense.org/defender/nyc-health-officials-bird-flu-summit-tabletop-simulated-plan/, 3 October 2024, by the same author (goes into more detail); and, www.theqtree.com/2024/08/02/the-hhs-gave-the-go-ahead-to-use-an-h5n1vaccine-but-the-ama-just-issued-new-cpt-codes-for-an-h5n8-vaccine/, 8 August 2024, by Yours Truly.

Note: the scientific paper referred to by Dr. Nevradakis is here: www.preprints.org/manuscript/202406.0060/v1, “Proximal Origin of Epidemic Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b and Spread by Migratory Waterfowl”, Nicolas Hulscher, John Leake, Peter McCullough, 3 June 2024; click on “Download PDF” to read or save the paper. The authors suspect Gain-of-Function to be in play. Below is the Abstract of the paper:

Since this paper is a preprint; and, that it may be a target for Retraction; Withdrawal; or, Reissue with “new conclusions” that would reflect pressure on the paper’s authors and/or the publisher, Yours Truly suggests that interested readers download or make a hard copy of the preprint version.

The International Bird Flu Summit was held in Fairfax, Virginia, on 2 – 4 October 2024. This is the website for the “summit”: https://birdflusummit.com/. Here is the Brochure for the “summit”: https://birdflusummit.com/Bird Flu Summit Brochure.pdf. Reading through these “summit” websites, one gets the distinct impression of a general tone that “a Bird Flu pandemic” is about to occur; and, that various “interventions”, “command and control” methods, and “monitoring and dismantling” of “misinformation” detected on social media platforms, etc., will be “necessary” as part of a “coordinated response.”

Taking a look at the Brochure for the “Bird Flu Summit”, here is a portion of one of the “overview” pages:

Seems innocuous enough. However, moving on in the Brochure, one finds this:

And, further along in the Brochure, there is this:

Military involvement? “Inter-agency Communication and Resource Allocation”? What is “Seamless Response”?

John Leake, who works with Dr. Peter McCullough, attended this “summit.” Here is his take: https://petermcculloughmd.substack.com/p/at-the-bird-flu-summit, 2 October 2024. Yours Truly agrees with his impression that the speakers at the “summit” were “middle-of-the-road, rather than barn-burning experts” (my phrase.) One also agrees with the impression that the “summit” was all about “a Bird Flu pandemic being just around the corner.” However, this is NOT to minimize the potential for something like a “bird flu epidemic / pandemic” occurring — either from a “natural cause”: or, by another “lab leak.” Here is another view on the situation: www.theburningplatform.com/2024/09/22/could-bird-flu-be-the-october-surprise/, by Clayton J. Baker, MD.

FLASH! — The McCullough Foundation just got a demand from one of the speakers at the “Bird Flu Summit”, Syra Madad, PhD, to delete a video that John Leake and Nicolas Hulscher (another McCullough Foundation member) made of a Question-and-Answer session between Mr. Leake and herself at the “summit.” Dr. Madad is the coordinator of the upcoming New York City “Bird Flu Response Conference.” Please see here: https://petermcculloughmd.substack.com/p/mccullough-foundation-receives-bird, “McCullough Foundation Receives Bird Flu Summit Censorship Demand”, 9 October 2024. Below is a portion of the article:

The transcript of the video follows in the article (the video was deleted.) Below is a portion of the transcript, followed by an assessment by Mr. Leake:

Turning to the entity that “presented” the event (Ginkgo Biosecurity), and the entity that “produced” the event (SyllabusX): this is where the “rabbit holes” emerge; and, something that Yours Truly will call the Big Pharma-Government-Medical Complex (BPGMCTM) comes into the situation. Yours Truly defines BPGMC as an “interwoven cooperation” among Big Pharma, Federal government agencies regarding development / funding / support (including the Department of Defense), institutional investors, private investors, and “Establishment Medicine” (CDC, FDA, AMA, etc.)

First, the “producer” of the “Bird Flu Summit”, SyllabusX. The company’s address and phone number: 1900 Campus Commons Dr., Suite 100, Reston, VA 20191; phone number: 703.466.0011. The company was founded in 2017. SyllabusX has its “fingers in many pies” regarding producing conferences and other events on student safety and security, on technology for educators, on health and biosecurity, and more (https://syllabusx.com/home-2; and, https://syllabusx.com/about-us.) (Note: it is not easy to find information online about this company, especially as regards financials. A couple of sources that Yours Truly found: https://pitchbook.com/profiles/company/520513-39#overview; and, www.zoominfo.com/c/syllabusx-inc/480230653.) It appears that SyllabusX is a “privately-held company.”

The Chief Research Officer of SyllabusX is Ahmed Al Faraj (www.linkedin.com/in/ahmed-al-faraj; Note: this link may not work, unless the reader first joins LinkedIn.) And here’s where the issue gets, IMO, interesting. It appears that Mr. Faraj graduated with a B.S. in Economics from the University of Kansas School of Business in 2006. His languages are listed as, “Native or bilingual proficiency” in Arabic.

Before starting SyllabusX, Mr. Faraj previously worked for a company called New-Fields Exhibitions, headquartered in Dubai (https://inf.ae/.) While at New-Fields Exhibitions, Mr. Faraj held positions as Program Manager, Education & Public Health Group; and. as Program Manager, Defense Business Group. Below are two screenshots from the type of work he performed while at New-Fields Exhibitions:

Mr. Faraj also previously worked for a company called AdvanFort. He was the Chief Operating Officer of this company. AdvanFort is owned by a person called Samir Farajallah. His son, the then-Chief Operating Officer, was called Ahmed Farahjallah. AdvanFort is “a US private maritime security company”, per Wikipedia. The company was founded in 2007, and its headquarters office is in Herndon, VA (www.advanfort.com/.) A vessel owned by AdvanFort was involved in an international maritime incident in 2014. One of the stories that covers this incident is here: www,bbc.com/news/uk-england-34095843, 7 September 2015, “AdvanFort accused of abandoning British men facing India trial.” As a result of this incident, AdvanFort withdrew from membership in SAMI (the Security Association for the Maritime Industry): https://gcaptain.com/sami-responds-accusations-from-advanfort/, 2 April 2014. (Interested readers may want to compare the photo of Ahmed Faraj on the SyllabusX LinkedIn site, to the photo of Samir Farajallah and Ahmed Farajallah that is in the BBC article linked above. In one’s opinion, the “Ahmed” in these photos is the same person, with a perhaps 10-year gap between the photos. One has no objection to people wishing to change their names — this is simply an interesting item.)

Second, the “presenter” of the “Bird Flu Summit” event, Ginkgo Biosecurity (Ginkgo Bioworks www.ginkgobioworks.com/.) The company’s address and phone number: 27 Drydock Ave., 8th Floor, Boston MA 02210; phone number: 877-HACK-DNA. The company works in “cell programming and biosecurity.” Ginkgo Biosecurity was founded in 2008 by students and scientists at MIT. Two of the founders are Tom Knight (known as the “godfather” of “DNA hacking” and of “synthetic biology” (www.prnewswire.com/news-releases/ginkgo-bioworks-to-become-a-public-company-and-expand-its-leading-platform-for-cell-programming-301288325.html, 11 May 2021; and, Austin Che https://startupexchange.mit.edu/watch/dinkgo-bioworks, 17 July 2017. Mr. Che is also a mentor for Creative Destruction Lab in Toronto, Canada (https://creativedestructionlab.com/mentors/austin-che/.) Below is a screenshot from the Ginkgo BioWorks website:

It appears that Ginkgo BioWorks has quite a bit of funding. Below are screenshots from https://tracxn.com/:

And, some institutional funders:

The United States government is also funding the biosecurity arm of Ginkgo BioWorks: www.dfc.gov/media/press-releases/dfc-approves-11-billion-loan-ginkgo-bioworks-expand-its-commercial-biosecurity, “DFC Approves $1.1 Billion Loan to Ginkgo BioWorks to Expand its Commercial Biosecurity Business to Combat COVID-19 on a Global Scale”, 25 November 2020. DFC is the U.S. International Finance Development Corporation. Below is a screenshot from the article:

For comparison, here is a list of some raw materials used in nucleic acid-based vaccines (mRNA-based vaccines), from www.promega.com/custom-solutions/custom-manufacturing/mrna-manufacturing/:

It would appear that Ginkgo BioWorks was involved in the “rapid deployment” of those PCR tests and antigen tests for COVID-19 at the start of the pandemic; and, also in the production of “two key raw materials for nucleic acid-based vaccines” (the modRNA COVID-19 “vaccines”.) Below is a blog post from April 2020 by Jason Kelly, another Ginkgo BioWorks co-founder, regarding the company’s partnership with Moderna in the production of the modRNA COVID-19 “vaccine”, mRNA-1273, along with other of that company’s mRNA “vaccines”:

Yours Truly has not, to date, found information as to the exact “raw materials” that Mr. Kelly is referring to.

Recall that the NIH/NIAID and Moderna co-developed mRNA-1273, co-own the patents of this modRNA COVID-19 “vaccine”, and share in the “royalty payments” for the sales and administration of this “vaccine” (and its “descendant clone” modRNA COVID-19 “vaccines.”)

Ginkgo BioWorks also “has its fingers in many pies”, including the bio-engineering of elements for gene therapy: www.ginkgobioworks.com/offerings/gene-therapy-services/. One such “service” is the bio-engineering of bacteria for treatment of diseases, such as cancer: www.ginkgobioworks.com/2023/01/09/engineering-bacteria-for-cancer-patient-treatment-with-prokarium/ (Prokarium is another “partner” with Ginkgo BioWorks.) The bacteria to be bio-engineered is a type of Salmonella bacteria, which will be used for “delivery of RNA payloads to treat cancer patients.” (Salmonella is “the most common form of food poisoning the in the U.S.”, according to the Cleveland Clinic. This brings up two questions: One, “Why is a bacteria related to food poisoning going to be used to treat cancer patients?”; and, Two, “How is this Salmonella bacteria going to be bio-engineered — is it going to be “sanitized” to be a beneficial element?”)

In Yours Truly’s opinion, Ginkgo BioWorks is a company to keep “on the radar.” It is acquiring other “partner companies” at a rapid rate. It is expanding its “services” into the gene-therapy sector. It is a “partner” with Moderna (and, therefore, by extension the NIH / NIAID.) In general, one has no objection to a company wishing to increase its profit margin and/or the number of its partner companies; at issue here are the following factors: the bio-engineering of DNA; the use of “automated tools” for engineering / manufacturing “raw materials” for gene-therapy treatments and/or “vaccines”; and the tie-in with the federal government.

General Summary: One: The International Bird Flu Summit was held in Fairfax, Virginia, earlier this month. The general tone of the “summit” was that a “bird flu epidemic / pandemic outbreak” is likely to occur, and soon. Two: The “summit” covered many topics related to epidemic / pandemic response, “command and control” methods, and how “seamlessly” federal, state and local governments and the military can “work together” in the response. Three: the “producer” of the “summit” was SyllabusX, a company that manages events ranging from student security to biosecurity to health education. SyllabusX is based in Virginia. Its Chief Research Officer is Ahmed Al-Faraj, who had previously (apparently) worked for his father’s company, AdvanFort, and (actually) for several other companies. Four: The “presenter” of the “summit” was Ginkgo Biosecurity (Ginkgo BioWorks), a company that offers “services” ranging from commercial biosecurity to bio-engineering to gene therapy research. This company, based in Massachusetts, has “deep funding” from many sources, including from the U.S. government. It has multiple “partners” in R&D, including Moderna. Ginko BioWorks was founded by students and scientists from MIT, including Tom Knight, the “godfather” of “DNA hacking” and of “synthetic biology.” Five: It appears that Ginkgo BioWorks, and, possibly, SyllabusX, are part of what may be called the Big Pharma-Government-Medical Complex (BPGMCTM), the “reach” of which runs far and wide.

Yours Truly will again emphasize the importance of having, and maintaining, the highest degree of health possible of the body’s natural immune system.

Peace, Good Energy, Respect: PAVACA